Pieris Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 50
- Market Cap
- $23.4M
- Website
- http://www.pieris.com
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
- Conditions
- HER2-positive Gastric Cancer
- Interventions
- Drug: Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxelDrug: Cinrebafusp alfa (PRS-343) in combination with tucatinib
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Pieris Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05190445
- Locations
- 🇺🇸
Sansum Clinic, Santa Barbara, California, United States
🇺🇸Maryland Oncology-Hematology, Silver Spring, Maryland, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
- Conditions
- HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder CancerHER2-positive Solid Tumor
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Pieris Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03650348
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸UCLA Health, Santa Monica, California, United States
PRS-343 in HER2-Positive Solid Tumors
- Conditions
- HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder CancerHER2-positive Solid Tumor
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Pieris Pharmaceuticals, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT03330561
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of California Los Angeles (UCLA), Santa Monica, California, United States
🇺🇸Georgetown University, Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
News
Ebenbuild Secures €2.3 Million EIC Grant to Advance Digital Twin Platform for Respiratory Drug Development
Ebenbuild received €2.3 million from the European Innovation Council Accelerator program to advance its AI-enabled digital twin platform for lung simulation and respiratory drug development.
HER2-Positive Gastric Cancer Pipeline Shows Robust Activity with 20+ Companies Developing Novel Therapies
DelveInsight's 2025 pipeline report reveals over 20 companies actively developing more than 20 innovative therapies for HER2-positive gastric cancer treatment.
Palvella Therapeutics Gains Analyst Attention with QTORIN Rapamycin Development for Rare Skin Diseases
• Palvella Therapeutics is developing QTORIN 3.9% rapamycin anhydrous gel for rare genetic skin diseases, addressing unmet needs. • Phase 3 trial data for microcystic lymphatic malformations (mLMs) is expected in early 2026, with potential market launch in 2027. • H.C. Wainwright initiated coverage with a Buy rating and a $38 price target, projecting peak sales of $381 million by 2034. • Palvella's merger with Pieris Pharmaceuticals provides financial stability with $80 million in cash reserves, supporting operations into 2027.